BioNano Genomics, Inc. (BNGO) Reports Q4 Net Loss of $29.5M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Nasdaq, S&P 500 decline with tech; investors assess softer jobs data
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Bionano Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022
March 1, 2022 4:05 PM ESTFull-year 2021 revenue growth of 111% over 2020Achieved publicly announced anticipated milestones for 2021Strong balance sheet with $250.6 million in cash, cash equivalents, and available-for-sale securities as of YE 2021Conference call today, March 1st, 2022 at 4:30 PM ET
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClincial, a leading software solution for... More
